文献速递贫血与红细胞疾病白血病

儿童自身免疫性溶血性贫血与基础免疫疾病高发相关

Pediatric autoimmune hemolytic anemia is associated with a high incidence of underlying immune disorders.
PubMed 文献 · Blood Adv · 2026-01-01

该多中心回顾性研究纳入15个儿科中心的399例自身免疫性溶血性贫血(AIHA)患儿,发现多数患儿存在继发性诊断,包括Evans综合征(37%)、其他自身免疫病(22%)和先天性免疫缺陷(IEI,18%)。复发/慢性病程与异常免疫检测、Evans综合征、IEI及其他自身免疫病相关,所有死亡患儿均有继发性诊断。

要点

  • 儿童AIHA常继发于Evans综合征、其他自身免疫病或IEI,需广泛免疫评估。
  • 复发AIHA与异常免疫检测、Evans综合征、IEI及其他自身免疫病显著相关。
  • 所有死亡患儿均有继发性诊断,提示需针对免疫诊断进行监测和靶向治疗。

核心结论

  • 儿童AIHA与基础免疫疾病高发相关,多数患儿存在继发性诊断。
  • 复发/慢性病程与异常免疫检测、Evans综合征、IEI及其他自身免疫病相关。
  • 所有死亡患儿均有继发性诊断,需广泛免疫评估和靶向治疗。

研究设计与样本

  • 回顾性多中心研究,纳入15个儿科中心的399例AIHA患儿。
  • 收集中位随访4.9年(范围0-19.4年)的数据,分析继发诊断、复发/慢性病程、疗效和死亡率。

主要发现

  • Evans综合征142/385(37%),其他自身免疫病86/392(22%),IEI 68/379(18%)。
  • 305例检测中82%功能免疫结果异常;109/348(31%)行IEI基因检测,其中32%发现致病性变异。
  • 257例温抗体型AIHA中72例(28%)在治疗中仍有活动性疾病;399例中10例死亡,均有继发性诊断。

关键数值与推荐

  • 首次AIHA发作中位治疗数为2(范围0-17)。
  • 温抗体型AIHA中31%在首次发作时接受激素节约治疗。

临床怎么用

  • 对儿童AIHA应进行广泛的免疫评估,包括功能免疫检测和IEI基因检测。
  • 监测并针对免疫诊断进行靶向治疗,以改善复发/慢性病程和预后。

局限性

  • 回顾性研究设计可能存在选择偏倚和信息偏倚。
  • 部分检测数据不完整(如基因检测仅31%患者完成)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pediatric autoimmune hemolytic anemia (AIHA) is a heterogeneous disease with significant morbidity due to the underlying condition and its treatment. Evidence-based guidelines for evaluation and management are lacking. Data from 399 patients with AIHA followed at 15 pediatric centers were collected to identify factors associated with secondary diagnoses, recurrent/chronic course, therapeutic efficacy, and mortality. Most had AIHA associated with secondary diagnoses including Evans syndrome (142/385 [37%]), other autoimmunity (86/392 [22%]), and inborn errors of immunity (IEI; 68/379 [18%]). Of 305 patients tested, 82% had abnormal functional immune results. Genetic testing for IEI was performed in 109 of 348 patients (31%), with pathogenic findings identified in 32% of those tested. Patients with IEI or other autoimmunity more frequently had abnormal immunoglobulin and complement testing. Prevalence of IEI was not different between those presenting with and without infection. The median number of treatments for the first AIHA episode was 2 (range, 0-17). Of those with warm AIHA, 31% received steroid-sparing therapy during the first episode. Patients with recurrent AIHA (42%) had a higher rate of abnormal immune tests (odds ratio [OR], 2.29; P = .012), Evans syndrome (OR, 4.85; P< .001), IEI (OR, 3.88; P< .001), and other autoimmune disorders (OR, 3.29; P< .001). With a median follow-up of 4.9 years (range, 0-19.4), 72 of 257 (28%) with warm AIHA continued to have active disease on treatment. Of the 399 patients, 10 died, all of whom had secondary diagnoses. Expansive immune evaluation, monitoring, and targeted treatments directed at immune diagnoses are needed for pediatric AIHA, highlighting the need for evidence-based pediatric AIHA guidelines.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Harris EM, Steele M, Kalashnikova T, et al. Pediatric autoimmune hemolytic anemia is associated with a high incidence of underlying immune disorders. Blood Adv. 2026. PMID: 42392173. doi:10.1182/bloodadvances.2026020023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。